Spots Global Cancer Trial Database for small cell lung cancer recurrent
Every month we try and update this database with for small cell lung cancer recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer | NCT00315211 | Mediastinal Neo... | Intravenous Top... Intravenous Doc... | 18 Years - | Aultman Health Foundation | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | NCT05815160 | Small Cell Lung... | Debio 0123 Etoposide Carboplatin | 18 Years - | Debiopharm International SA | |
| Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation | NCT02477813 | Small Cell Lung... | Temozolomide | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | NCT03262454 | Small Cell Lung... | Atezolizumab | 18 Years - | National Cancer Center, Korea | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | NCT01441297 | Small Cell Lung... Small Cell Lung... | BIBF 1120 | 18 Years - | National Cancer Center, Korea | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | NCT03262454 | Small Cell Lung... | Atezolizumab | 18 Years - | National Cancer Center, Korea | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
